Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 19INDUSTRY 9NIH 3NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Sarcoma 2Triple Negative Breast Neoplasms 1Rectal Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Bone Neoplasms 1

Interventions

Cyclophosphamide 2palbociclib 1olaparib 1fludarabine 1durvalumab 1binimetinib 1atezolizumab 1Methotrexate 1Cisplatin 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Triple Negative Breast Neoplasms × olaparib × Clear all
NCT05209529 2024-02-23

Chemo-free BRCA-targeted Neoadjuvant Strategy

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡